Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL

NCT04494503 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

123

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions

DRUG: APG-2575
DRUG: Rituximab
DRUG: Ibrutinib

Sponsor

Ascentage Pharma Group Inc.